Novo Nordisk and Eli Lilly are facing scores of personal injury claims for allegedly failing to warn patients about side ...
It’s hard to watch the news or scroll through social media without encountering stories about weight loss drugs like ...
Courts have long deferred to CMS’s decisions on implementation of laws that govern Medicare. The overturning of the Chevron ...
Biotech companies are racing to find Ozempic 2.0, hoping for a slice of a multi-billion-dollar industry. A few stand-out ...
Wegovy: Novo Nordisk’s name-brand version of injectable semaglutide to help adults and children 12 years and older with ...
Ozempic and related GLP-1 drugs have taken Europe and North America by storm and have quickly become the darling of the ...
ThePrint on MSN6d
Ozempic on steroids? Successor that could cut down weight in half the time coming soonWhile Novo Nordisk says CagriSema will help users lose up to 25% of weight, duration will be clear when final results of its ...
However, the clock is ticking. Novo Nordisk already has an oral semaglutide to treat type 2 diabetes, sold under the brand name Rybelsus, and they're trialing a high-dose version of that pill that ...
Zacks.com on MSN4d
Amgen Shrugs Off Bone Density Concerns Related to Obesity CandidateKey Takeaways Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's ...
Novo Nordisk gets CHMP backing for oral GLP-1 agonist Rybelsus in its marketing battle with Eli Lilly, plus positive opinions for Bayer’s diabetes drug Nubeqa, Emergent’s cholera vaccine, and more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback